Biomarin Pharmaceutical (BMRN) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09061G1013

(NASDAQ:BMRN Stock) BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California. Web URL: https://www.biomarin.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Biomarin Pharmaceutical (BMRN) - Stock & Dividends

BMRN Stock Overview

Market Cap in USD 16,591m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1999-07-23

BMRN Stock Ratings

Fundamental 0.05
Dividend -
Growth 5y 0.46
Rel. Performance vs Sector -2.82
Analysts 4.24
Fair Price Total Ret. 80.91
Fair Price DCF 4.46

BMRN Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

BMRN Growth Ratios

Growth 12m -14.14%
Growth Correlation 12m -23%
Growth Correlation 3m -24%
CAGR 5y -0.62%
CAGR / Mean Drawdown -0.02
Sharpe Ratio 12m -0.66
Alpha vs SP500 12m -34.48
Beta vs SP500 5y weekly 0.71
CAPM 7.18%
Average Daily Range 2m 2.27%
Regime Oscillator 47.55
Volatility GJR Garch 1y 36.05%
Price / SMA 50 -4.74%
Price / SMA 200 -1.6%
Current Volume 1268.4k
Average Volume 20d 1373.2k

External Links for BMRN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of BMRN stocks?
As of February 22, 2024, the stock is trading at USD 88.54 with a total of 1,268,429 shares traded.
Over the past week, the price has changed by +2.94%, over one month by -5.85%, over three months by +0.55% and over the past year by -16.45%.
Why is BMRN stock down?
Check with which Index or Commodity BMRN has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return BMRN Return S&P 500
1 Month -5.85% 2.85%
3 Months 0.55% 10.14%
12 Months -16.45% 26.48%
What is the forecast for BMRN stock price target?
According to ValueRays Forecast Model, BMRN Biomarin Pharmaceutical will be worth about 87.8 in February 2025. The stock is currently trading at 88.54. This means that the stock has a potential downside of -0.88%.
Issuer Forecast Upside
Wallstreet Target Price 110.4 24.7%
Analysts Target Price 117 32.1%
ValueRay Target Price 87.8 -0.9%